Furthermore, data from patient cohorts confirm that low expression of ZNF217 (Supplemental Fig. S7A; Győrffy et al. 2009; Frietze et al. 2014) and high expression of miR-503 (Supplemental Fig. S7B; Antonov 2011; Lyng et al. 2012; Antonov et al. 2013) in breast cancer is significantly associated with improved survival (P = 0.038 for ZNF217 and P = 0.000437 for miR-503). Here, ZNF217 is linked to breast cancer.